NL-OMON20186
Not yet recruiting
Not Applicable
Comparison of subcutaneous and intravenous continued treatment with ultra-low dose Rituximab in rheumatoid arthritis: a randomised open-label non-inferiority trial
ConditionsRheumatoid arthritis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rheumatoid arthritis
- Sponsor
- Sint Maartenskliniek
- Enrollment
- 36
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •Rheumatoid arthritis: either 2010 EULAR/ACR RA17 and/or 1987 ACR RA18 criteria and/or clinical diagnosis of the treating rheumatologist;
- •Patients using rituximab in ultra\-low dose: either 200 mg or 500 mg as previous dose, given every 6 months, with or without concomitant methotrexate;
- •Having sufficient response to rituximab treatment, operationalized as a DAS28\-CRP \<2\.9 3\-6 months after the last infusion and/or judgment of low disease activity by the treating rheumatologist;
- •\=16 years old and mentally competent;
- •Ability to read and communicate well in Dutch.
Exclusion Criteria
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •Previous non\-response to ultra\-low dose rituximab (DAS28\-CRP \> 2\.9\);
- •Objection or contraindication to either of the treatment options;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Research into administration of lower dosed rituximab with an injectiorheumatoid arthritisMedDRA version: 21.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2020-002507-19-NLSint Maartenskliniek36
Completed
Phase 2
Comparison of two methods of administration of deferoxamine (intravenous and subcutaneous) in terms of impact on reducing iron overload in thalassemia patients who have suffered heart failure.Iron overload..Abnormal level of blood mineral.IRCT201206289827N2Kermanshah University of Medical Sciences and Health Services42
Completed
Phase 2
A study to compare the effect of dexmeditomidine on block characteristics when given by two different route perineural and intravenous along with supraclavicular brachial plexus block with bupivacaine in upper limb surgery.Health Condition 1: O- Medical and SurgicalHealth Condition 2: O- Medical and SurgicalCTRI/2020/02/023652JAWAHARLAL NEHRU HOSPITAL AND RESEARCH CENTRE50
Recruiting
Phase 2
Comparing the effectiveness of intravenous and sublingual administration of midazolam for sedation of patients who are candidates for upper gastrointestinal endoscopy.The effect of medicine on the level of sedation, pain and discomfort and satisfaction of patients who are candidates for upper gastrointestinal endoscopy.IRCT20100102002963N36Yazd University of Medical Sciences80
Active, not recruiting
Not Applicable
Comparison with subcutaneous injections using a needle-free injection systemrubella , measlesJPRN-jRCTs031220030Takazawa Kenji40